In two of three phase 3 trials , pirfenidone , an oral antifibrotic therapy , reduced disease progression , as measured by the decline in forced vital capacity ( FVC ) or vital capacity , in patients with idiopathic pulmonary fibrosis ; in the third trial , this end point was not achieved .